CellaVision (CLVS.F) Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
CLVS.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 17.30 |
| 52 Week High | SEK 17.30 |
| 52 Week Low | SEK 16.69 |
| Beta | 1.35 |
| 1 Month Change | 2.82% |
| 3 Month Change | n/a |
| 1 Year Change | -10.27% |
| 3 Year Change | -15.69% |
| 5 Year Change | -50.97% |
| Change since IPO | 850.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLVS.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.8% | -2.2% | -0.3% |
| 1Y | -10.3% | -6.4% | 13.0% |
Return vs Industry: CLVS.F underperformed the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: CLVS.F underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| CLVS.F volatility | |
|---|---|
| CLVS.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLVS.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CLVS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 231 | Simon Ostergaard | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials.
CellaVision AB (publ) Fundamentals Summary
| CLVS.F fundamental statistics | |
|---|---|
| Market cap | US$417.24m |
| Earnings (TTM) | US$16.81m |
| Revenue (TTM) | US$83.08m |
Is CLVS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLVS.F income statement (TTM) | |
|---|---|
| Revenue | SEK 748.45m |
| Cost of Revenue | SEK 231.20m |
| Gross Profit | SEK 517.25m |
| Other Expenses | SEK 365.85m |
| Earnings | SEK 151.41m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 05, 2026
| Earnings per share (EPS) | 6.35 |
| Gross Margin | 69.11% |
| Net Profit Margin | 20.23% |
| Debt/Equity Ratio | 3.2% |
How did CLVS.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 18:12 |
| End of Day Share Price | 2026/01/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CellaVision AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |